Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
7 Innovator Stocks Primed for Exceptional Growth
06:46pm, Tuesday, 10'th Oct 2023
Artificial intelligence. New pharmaceutical drugs.
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus
12:47pm, Tuesday, 10'th Oct 2023
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
07:32pm, Monday, 09'th Oct 2023
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $56.61, indicating a -0.09% shift from the previous trading day.
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
05:16pm, Monday, 09'th Oct 2023
CNBC's Angelica Peebles joins 'Closing Bell: Overtime' to discuss Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion
Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma
05:13pm, Monday, 09'th Oct 2023
Tesla (TSLA) shares are in focus as China-made EV demand drops by 10%, affecting Model 3 and Y sales. Tesla's delivery and production data declined from last quarter following a report by the China Pa
Pharma Stock Nears 2-Year Low on Multi-Billion Dollar Deal
02:10pm, Monday, 09'th Oct 2023
Shares of major pharmaceutical name Bristol-Meyers Squibb Co (NYSE:BMY) are 0.2% lower at $56.54 at last glance, and touched a nearly two-year low of $55.70, after the company agreed to acquire Mirat
Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics
01:04pm, Monday, 09'th Oct 2023
Bristol-Myers Squibb Co (NYSE: BMY) has decided to spend up to $5.8 billion to acquire Mirati Therapeutics Inc (NASDAQ: MRTX). Shares of both companies are in the red at writing.
Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio
12:05pm, Monday, 09'th Oct 2023
Bristol-Myers Squibb (BMY) moved to expand its reach into cancer-fighting drugs by buying Mirati Therapeutics (MRTX) in an all-cash deal for what could total $5.8 billion.
Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B
12:02pm, Monday, 09'th Oct 2023
Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.
Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal
11:40am, Monday, 09'th Oct 2023
Bristol Myers Squibb will buy Mirati Therapeutics in a deal worth up to $5.8 billion, or $58 per share, the biopharmaceutical company announced Sunday.
Bristol-Myers Squibb to acquire Mirati in deal worth up to $5.8B
10:48am, Monday, 09'th Oct 2023
Bristol-Myers Squibb (BMY) agreed to buy cancer drugmaker Mirati Therapeutics (MRTX) for up to $5.8 billion. The deal will help Bristol-Myers Squibb bring new drugs into their pipeline as some of thei
Bristol-Myers Squibb enhances oncology portfolio in deal worth up to $5.8bn
06:16am, Monday, 09'th Oct 2023
Bristol-Myers Squibb Co (NYSE:BMY) has unveiled plans to buy Mirati Therapeutics (NASDAQ:MRTX) in a deal that values the cancer drug developer at up to $5.8 billion. This acquisition aims to diversi
Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 Billion
05:27am, Monday, 09'th Oct 2023
The acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb's best-selling products.
Bristol-Myers Squibb enahnces oncology portfolio in deal worth up to $5.8bn
03:21am, Monday, 09'th Oct 2023
Bristol-Myers Squibb Co (NYSE:BMY) has unveiled plans to buy Mirati Therapeutics (NASDAQ:MRTX) in a deal that values the cancer drug developer at up to $5.8 billion. This acquisition aims to diversi
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion
07:34pm, Sunday, 08'th Oct 2023
Bristol Myers Squibb Co. said Sunday it will buy Mirati Therapeutics Inc. in a deal valued at up to $5.8 billion.
